BioCryst to Report Second Quarter 2024 Financial Results on August 5
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced that it will release its second quarter 2024 financial results on Monday, August 5, 2024. The company's management team will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update. Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). Additionally, a live webcast and replay of the call will be available in the investors section of the company's website at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il lunedì 5 agosto 2024. Il team dirigenziale della società ospiterà una conf call e webcast alle 8:30 ET lo stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale. Le parti interessate possono accedere alla chiamata in diretta componendo 1-844-481-2942 (nazionale) o 1-412-317-1866 (internazionale). Inoltre, sarà disponibile un webcast dal vivo e la registrazione della chiamata nella sezione investitori del sito web dell'azienda all'indirizzo www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el lunes 5 de agosto de 2024. El equipo de gestión de la compañía realizará una llamada de conferencia y webcast a las 8:30 a.m. ET el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa. Las partes interesadas pueden acceder a la llamada en vivo marcando 1-844-481-2942 (nacional) o 1-412-317-1866 (internacional). Además, se podrá acceder a un webcast en vivo y a la repetición de la llamada en la sección de inversores del sitio web de la compañía en www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 2024년 2분기 재무 결과를 2024년 8월 5일 월요일에 발표할 것이라고 발표했습니다. 회사의 경영진은 같은 날 오전 8시 30분 ET에 재무 결과에 대해 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 주최합니다. 관심 있는 당사자는 1-844-481-2942 (국내) 또는 1-412-317-1866 (국제)로 전화를 걸어 라이브 콜에 접속할 수 있습니다. 또한, 라이브 웹캐스트와 콜의 다시 시청할 수 있는 기록은 회사 웹사이트의 투자자 섹션(www.biocryst.com)에서 제공될 것입니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le lundi 5 août 2024. L'équipe de direction de l'entreprise organisera une conférence téléphonique et un webcast à 8h30 ET le même jour pour discuter des résultats financiers et fournir une mise à jour de l'entreprise. Les parties intéressées peuvent accéder à l'appel en direct en composant le 1-844-481-2942 (domestique) ou le 1-412-317-1866 (international). De plus, un webcast en direct et une rediffusion de l'appel seront disponibles dans la section investisseurs du site web de la société à l'adresse www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Montag, den 5. August 2024 veröffentlichen wird. Das Management-Team des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um über die Finanzergebnisse zu sprechen und ein Unternehmensupdate zu geben. Interessierte Parteien können den Live-Anruf unter 1-844-481-2942 (inländisch) oder 1-412-317-1866 (international) erreichen. Darüber hinaus wird ein Live-Webcast sowie eine Wiederholung des Anrufs im Investorenbereich der Unternehmenswebsite unter www.biocryst.com verfügbar sein.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When will BioCryst Pharmaceuticals (BCRX) report its Q2 2024 financial results?
What time is BioCryst's (BCRX) Q2 2024 earnings call scheduled for?
How can investors access BioCryst's (BCRX) Q2 2024 earnings call?
Where can I find the replay of BioCryst's (BCRX) Q2 2024 earnings call?
